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We report here the study design and baseline patient characteristics.
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58 A. Garcia-Cebrian et al. / European Psychiatry 23 (2008) 57e65depression norms (mean 45.0). Mean EQ-5D scores were also lower than general population norms. Mean HADS-Depression and -Anxiety sub-
scores were 12.3 and 13.0, respectively. Fifty-six percent of patients reported an overall pain VAS score of at least 30 mm and 70% of these
patients had no physical explanation for their pain.
Further investigation into factors associated with HRQoL in depression after treatment initiation is warranted.
 2007 Elsevier Masson SAS. All rights reserved.
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Depression is a common psychiatric disorder, with preva-
lence of major depression in Europe at around 5% [37]. The
European Study of Epidemiology of Mental Disorders
(ESEMeD) reported an overall annual prevalence of 3.9% for
major depression and a lifetime prevalence of 12.8% [16].
Prevalence varies across European countries and between urban
and rural settings [2,16].
Currently, depression is the fourth leading cause of disease
burden worldwide, and it is estimated that by 2020 it will be
the second [34]. The high disease burden is reflected in asso-
ciated morbidity and mortality. Patients with depression have
reduced functioning and impaired health-related quality of
life (HRQoL) [21,25,46]. Depression is also associated with
increased healthcare service utilisation and increased societal
costs, such as costs due to work days lost [22,37].
Although the efficacy of antidepressant medications and
psychotherapeutic treatments is well established [19], their
effectiveness in improving a broad range of outcomes is less
clear. The goal of treatment is to achieve remission (generally
defined as no or minimal symptoms and a return to normal
functioning) as this is associated with a lower risk of relapse
[29]. Various factors have been reported to influence the likeli-
hood of achieving remission, including the severity and chro-
nicity of depression and demographic factors such as ethnicity,
gender, employment, education or income [39]. Other factors
are the presence or absence of anxiety symptoms, painful
physical symptoms, co-morbidities and adherence to treatment
[3,10,17,38,40]. It is less well understood to what extent these
factors influence patient functioning and HRQoL.
Remission is assessed by prospective studies, particularly
randomised controlled trials (RCTs). The generalisability of
these results is often limited by the selectivity of the participat-
ing patients. As HRQoL may be affected by multiple factors,
observational longitudinal studies can determine outcomes in
a heterogeneous group of patients who receive treatment or
intervention in routine practice. Differences in healthcare sys-
tems and access to healthcare (country, urban/rural setting or
primary/specialist care) could be important factors in addition
to patient characteristics in assessing outcomes.
Factors Influencing Depression Endpoints Research
(FINDER) is a multinational study designed to increase the
understanding of the factors that influence HRQoL outcomes
for patients with a depressive episode in primary and specialist
care settings. The main objective of the study is to estimate
HRQoL at baseline (untreated) and at 3 and 6 months aftercommencing antidepressant therapy. In addition, it aims to de-
scribe the relationship between variables at baseline (including
depression, anxiety, somatic and pain symptoms), and to de-
scribe the impact that baseline factors and treatment choices
have on outcomes at 3 and 6 months.
The present paper reports the study design and describes the
characteristics of the study population at baseline. A further
paper describes the baseline prescribing patterns of initial
antidepressants in the European countries participating in
FINDER and the factors influencing initial antidepressant
choice [7].
2. Methods2.1. Study designFINDER is a 6-month, observational, naturalistic, multi-
centre study conducted in 12 European countries: Austria, Bel-
gium, France, Germany, Ireland, Italy, Netherlands, Norway,
Portugal, Sweden, Switzerland and the UK. Patients were
enrolled between May 2004 and September 2005. The study
had a non-interventional design, with all treatment decisions
at the discretion of the participating physician. Data were
collected at baseline (the routine visit at which the patient
agreed to enter the study) and at 3 and 6 months post-baseline
during visits that were part of routine clinical care.
The study was approved in all countries according to local
requirements for ethics and/or regulatory approvals for observa-
tional studies. Subsequent to clinical diagnosis and the decision
to treat with an antidepressant, patients gave written informed
consent for the provision and collection of data during the
observation period.
2.1.1. Patients
Patients were eligible for inclusion if they presented within
the normal course of care and (1) were clinically diagnosed by
their physician as suffering from depression, (2) were about to
start antidepressant pharmacological treatment for either a first
or subsequent episode of depression (the index episode), (3)
were aged at least 18 years, and (4) were not simultaneously
participating in another study that involved an investigational
drug or procedure.
2.1.2. Investigators
Participating investigators were primary care physicians
(PCPs) or specialists. Across the 12 participating European
countries, eligible patients were enrolled by 437 investigators
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other specialities [51.7%]). Although type and proportion of
investigators varied by country (Fig. 1), it most often reflected
country-specific variations in healthcare delivery. Demo-
graphic data on age and gender of investigators were collected.
FINDER included investigators from rural (62.7%) and urban
(27.3%) locations as well as public and private facilities.2.2. Data collection and assessmentsData were collected on local language forms at baseline,
and at 3 and 6 months (1 month) post-baseline. Any patients
not making a routine visit to their physician within the defined
data collection interval were retained in the study and could
have data collected the next time they presented within
a data collection interval.
2.2.1. Patient characteristics
At baseline, data on socio-demographics, psychiatric his-
tory and the occurrence of psychiatric disorders in the previous
24 months were prospectively collected by the physician based
on patient interviews. The presence of specified co-morbid
chronic physical conditions and functional syndromes in the
previous 24 months was recorded, as was whether or not the
patient had suffered any physical trauma in the previous 24
months, or whether they had presented with physical symp-
toms in the previous 24 months for which a cause could not
be identified.
Healthcare resource utilisation and psychotherapy in the
previous 24 months were recorded as well as use over the 3
and 6 month follow-up periods (psychotherapy data were not
collected in the UK). For the same periods, data regarding
the intake of antidepressants and analgesics (both over-the-
counter and prescribed) were also collected. Antidepressant0
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No.investigators 437 18 33 103 65
No. patients enrolled 3515 164 240 612 674
No. patients eligible 3468 163 239 606 649
Fig. 1. Investigators (%) who enrolltype, mean daily dose, start and stop date, and reason for dis-
continuation were recorded. Information on other prescribed
concomitant medications (mood stabilisers, anxiolytics/hyp-
notics and antipsychotics) taken at the time of entry into the
study and since study entry was collected at the 3 month (all
countries except the UK) and 6 month (all countries) visits.
2.2.2. Health-related quality of life (HRQoL) assessment
HRQoL was assessed at baseline, and 3 and 6 months using
the 36-item Short-Form Health Survey (SF-36) version 2 [45]
and the European Quality of Life-5 Dimensions (EQ-5D)
questionnaire [11].
The SF-36 is a widely used, self-administered, generic in-
strument for measuring HRQoL. Thirty-six questions generate
scores across eight health domains (subscales) and two sum-
mary scores: the physical component score (PCS) and the
mental component score (MCS). Norm-based scoring was
used for all eight SF-36 domains, with a mean of 50 and a stan-
dard deviation (SD) of 10 based on general US population
data, as European norms for all participating countries are un-
available at present but US norms correlate highly with exist-
ing country-specific measures and are recommended to be
used in multinational studies [44]. Norms for clinical depres-
sion were available for PCS (mean 45.0 [SD 12.1]) and
MCS (mean 34.8 [SD 12.2]). Higher scores indicate better
HRQoL.
The EQ-5D is a validated instrument for measuring health
outcomes consisting of two parts [11]: (1) a Visual Analogue
Scale (VAS) assessing overall health on the day scoring from
0 (worst imaginable health state) to 100 (best imaginable
health state); and (2) five questions covering mobility, self-
care, usual activities, pain/discomfort and anxiety/depression,
each scored on a 3-point scale (1¼ no problems, 2¼ some/
moderate problems, and 3¼ extreme problems). For eachIre
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ed eligible patients by country.
Table 1
Baseline socio-demographic characteristics of the study patient population
Patients
Enrolled patients (N ) 3515
Patients eligible for analysis (N ) 3468
Mean (SD) age [range] (years) 46.8 (14.7) [18e93]
Gender female/male (%) 68.2/31.8
No or mandatory level of educationa (%) 52.3
b
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were converted to a single Health State Index (HSI) on a scale
ranging from 0 to 1, with a higher score indicating better
HRQoL [15]. For both SF-36 and EQ-5D, official language
versions were available for all participating countries.
2.2.3. Depression assessment
The patient-rated Hospital Anxiety and Depression Scale
(HADS) [48] was completed at baseline and 3 and 6 months.
The HADS consists of seven items each for depression
(HADS-D) and anxiety (HADS-A) scored on a 4-point scale
from 0 to 3. For both subscales, a score of 11 indicates
‘probable case’ (i.e. probable presence of the mood disorder),
8e10 indicates ‘doubtful case’ and 7 indicates ‘non-case’
[48]. For analysis, all items within each HADS subscale had
to be answered otherwise the subscale was set to missing.
As published normative data for the HADS are limited, values
obtained from a general UK adult population were used for
reference purposes [14].
2.2.4. Somatic and pain assessment
Painful symptoms were evaluated at baseline, and 3 and
6 months using the 28-item Somatic Symptom Inventory
(SSI-28) [6] and six VAS [9] with the aim of exploring pos-
sible relationships between depression, HRQoL and pain.
The SSI-28 consists of seven pain-related items and 21
items not relating to pain. Patients rated the degree to which
each symptom bothered them over the past week on a scale
of 1 (not at all) to 5 (a great deal).
Overall pain severity was rated by patients using a horizon-
tal VAS marked ‘no pain’ at one end (0 mm) and ‘as severe
as I can imagine’ at the other end (100 mm), as were each of
the following: headaches, back pain, shoulder pain, interfer-
ence with daily activities and time in pain while awake.
Patients with an overall pain VAS score of 30 mm or more
were defined as having ‘moderate/severe pain’ [13,30]. This
threshold score together with the presence of chronic condi-
tions was used to stratify patients into three groups: (1) no/
mild pain; (2) moderate/severe pain with a defined co-morbid
chronic physical condition and/or co-morbid functional
syndrome present known to cause pain, termed ‘medically
explained pain’; and (3) moderate/severe pain with a defined
co-morbid physical condition and/or co-morbid functional
syndrome present but not associated with pain, or those with-
out further co-morbidity, termed ‘medically unexplained
pain’. Pain in the study population was further characterised
by analysing the SF-36 bodily pain domain and the EQ-5D
pain/discomfort item.Cohabiting (%) 58.6
Unemployed (%) 13.7
In paid work (%) 50.12.3. Statistical analysis
Mean (SD) number of dependants 1.1 (1.3)
Mean (SD) BMI (kg/m2) 25.5 (5.2)
Current smoker (%) 32.3
BMI: Body Mass Index; SD: standard deviation.
a Reference is further, university or post-graduate education.
b Includes married or domestic partner vs. divorced, legally separated,
widowed, partner living separate or no relationship.Descriptive summary statistics (means, standard deviations
[SDs], frequencies, percentages) were used to describe the
baseline characteristics of the study population. Longitudinal
data from the FINDER study will be presented in a follow-up
publication.Patients were excluded from the analysis if one or more en-
try criteria were violated or from individual analyses based on
missing, implausible (according to pre-defined ranges) or un-
interpretable data. The exclusion of patients’ data from analysis
was based on study entry criteria at the first observation, not on
whether or not antidepressant medication was taken during the
6 month follow-up period. Only 47 patients were excluded
from the analysis (1.3%) due to failure to meet any of the entry
criteria. Data were analysed using SAS version 8.2.
3. Results
In total, 3515 patients were enrolled and data from 3468
(98.7%) were eligible for analysis. Most patients were enrolled
in Germany, France, UK and Italy, with fewer than 100 patients
each from Ireland, Portugal and Norway (Fig. 1).3.1. Patient characteristics and psychiatric
and medical historiesPatients’ socio-demographic characteristics are presented in
Table 1.
Regarding psychiatric history, patients had a mean duration
of depressive illness of 8.5 years (SD 10.4) and 45.1% had a his-
tory of at least one other depressive episode in the previous 2
years (excluding the index episode) (Table 2). Anxiety disorder
and/or panic disorder in the previous 2 years were also common
(51.1%).
The mean duration of the current episode of depression was
13.6 weeks (SD 16.5). For patients who had previous episodes
of depression, the mean time between remission of the previ-
ous episode and onset of the index episode was 24.8 weeks
(SD 20.1).
A large proportion of patients had at least one co-morbid
chronic physical condition (42.5%) or co-morbid functional
syndrome (39.9%) at study entry (Table 3). Hypertension
was the most common co-morbid chronic physical condition
(20.0%) and chronic fatigue syndrome was the most common
co-morbid functional syndrome (25.3%).
Table 2
Psychiatric history of patients at the baseline visit
Patients
Previous depression episodes
Mean (SD) duration of depressive illness [range]
(years)
8.5 (10.4) [0e71]
Mean (SD) age at first episode [range] (years) 38.4 (14.7) [14e91]
Percentage of patients who had at least one
other depressive episode in previous 2 years
(excluding index episode)
45.1
Mean (SD) number of depressive episodes in
previous 2 years (excluding index episode)
[range]a
1.8 (1.4) [1e20]
Mean (SD) duration of the depressive episode
(weeks) preceding index episode [range]a
17.1 (14.5) [1e96]
Current (index) episode of depression
Mean (SD) duration [range] (weeks) 13.6 (16.5) [1e104]
Mean (SD) time between previous episode’s
remission and onset of index episode [range]
(weeks)a
24.8 (20.1) [1e98]
Other psychiatric disorders in previous 2 yearsb
Anxiety disorder and/or panic disorder (%) 51.1
Obsessive compulsive disorder (%) 9.0
Drug and/or alcohol dependence disorder (%) 6.9
SD: standard deviation.
a Only for patients who had a previous episode of depression within 2 years.
b Reported if >5%. Others from selected list were bipolar disorder and
schizophrenia.
Table 3
Co-morbid chronic physical conditions and functional syndromes at the base-
line visit
Patients
Patients with at least one co-morbid chronic physical
conditiona (%)
42.5
Mean (SD) number of co-morbid chronic physical
conditionsa
0.7 (1.1)
Patients with different types of co-morbid chronic
physical conditionsb (%)
Hypertension 20.0
Rheumatological disorder 10.9
Asthma 6.7
Diabetes 5.7
Other (than neuropathic) neurological disorder 5.3
Patients with at least one co-morbid functional
syndromec (%)
39.9
Mean (SD) number of co-morbid functional syndromesc 0.7 (1.1)
Patients with different types of functional
syndromesd (%)
Chronic fatigue syndrome 25.3
Irritable bowel syndrome 16.1
Atypical chest pain 11.1
Irritable bladder 7.4
Fibromyalgia 7.0
SD: standard deviation.
a Listed conditions were diabetes, angina, hypertension, asthma, malignant
disease, neuropathic disorder, other neurological disorder, rheumatologic dis-
order, other chronic condition.
b Reported in table if >5%. Angina, neuropathic disorder and malignant dis-
ease were present in 3.7%, 2.7% and 2.5% of patients, respectively. Other
chronic conditions were present in 14.3% of all patients.
c Listed conditions were irritable bowel syndrome, chronic fatigue syn-
drome, atypical chest pain, irritable bladder, fibromyalgia, chronic pelvic pain.
d Reported in table if >5%. Chronic pelvic pain was present in 4.9% of
patients.
61A. Garcia-Cebrian et al. / European Psychiatry 23 (2008) 57e653.2. Baseline scoresFig. 2 shows SF-36 scores with the mean MCS (22.2, SD
10.0) and mean PCS (46.1, SD 10.3) plotted together with
general population and clinical depression norms.
The mean scores of the EQ-5D HSI and VAS for the study
population (Table 4) were just over half of those of European
population norms. Problems were most often recorded in the
anxiety/depression, pain/discomfort and usual activities di-
mensions of the EQ-5D. Almost three-quarters (73.3%) of pa-
tients had moderate or extreme pain/discomfort on the EQ-5D
pain/discomfort domain (Table 5).
The mean HADS-D score (12.3, SD 4.5) of the study pop-
ulation was much higher than that of the UK general adult
population (3.7, SD 3.1) [14] (Table 4). On the basis of
HADS-D cut-offs, 66.3% of all patients were considered to
be probable cases of depression, 18.5% were doubtful cases
and 15.2% were non-cases. The patients also had a higher
mean HADS-A score (13.0, SD 4.0) than the UK general adult
population (6.1, SD 3.8). Of the patients in this study, 74.1%
were probable cases of anxiety, 16.6% were doubtful cases
and 9.3% were non-cases for anxiety.
The mean overall pain VAS score was 39.6 (SD 28.8).
Mean scores for all VAS pain scales are summarised in Table 5.
Pain interfered with work at least moderately in 55.1% of
patients (SF-36 single item). Of the different locations of
pain symptoms (SSI-28), headaches were the most common
(Table 5).3.3. Relationship between depression, HRQoL
and pain at baselineWith respect to the three pain groups, 1447 patients
(43.7%) had no/mild pain, 1311 (39.6%) had medically unex-
plained moderate/severe pain and 550 (16.6%) had medically
explained moderate/severe pain. In the first group, mean
scores on the SF-36 bodily pain domain and PCS were at least
one SD higher than in patients with medically explained pain
or medically unexplained pain (Fig. 3).
The mean HADS-D score at baseline was higher in pa-
tients with six or seven pain-related items on the SSI-28
than in those with fewer pain symptoms (Fig. 4). The mean
HADS-D score also increased with increasing pain severity
on the EQ-5D pain/discomfort dimension: no pain/discomfort,
11.4 (SD 4.6); moderate, 12.3 (SD 4.3); and extreme, 14.4
(SD 4.2).
4. Discussion
There is increasing debate in the healthcare literature about
the ‘efficacy gap’ and assessment of the ‘relative effectiveness’
of healthcare interventions, especially for publicly funded
healthcare systems where demand always exceeds available re-
sources [20] and where physicians and decision-makers must
choose between different treatments [28]. By providing further
information about the management of depressed patients in
real life settings, observational studies complement RCT
Table 5
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Fig. 2. Mean SF-36 domain scores and mental and physical health component summary scores (all norm-based) for the study population at baseline. Dotted line
represents the general population norm (mean 50). Solid lines represent clinical depression norms (PCS mean 45.0; MCS mean 34.8). A higher score indicates
better quality of life. PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional;
MH, mental health; MCS, mental component score; PCS, physical component score.
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treatments on patient outcomes [31]. FINDER was designed to
provide further information and increase the understanding of
the factors that influence HRQoL outcomes for patients
receiving antidepressant medication for a depressive episode
in routine primary and specialist care settings. A few study de-
sign characteristics are of note: (1) the setting in primary and
secondary care; (2) criteria for patient inclusion; and (3) longi-
tudinal design. The second objective of this paper, the charac-
teristics of the FINDER study population, will also be
discussed.Pain assessment at baseline
Measure Patients N (%)
4.1. Primary and secondary care settingsPain severity, EQ-5D pain/discomfort domain
None 918 (26.7)
Moderate 2100 (61.2)
Extreme 414 (12.1)
Pain interference with normal work, SF-36 single itemFINDER, unlike other large European observational
studies [2,8,16,33,42], includes patients in primary and spe-
cialist care. Most episodes of depression and anxiety areTable 4
EQ-5D and HADS scores at baseline for the total patient population
Study population General population
EQ-5D European countries (N¼ 21,004)a
Health State
Index score (0e1)
0.44 (0.31) 0.85 (0.23)
VAS score (0e100) 44.8 (20.4) 77 (20)
Dimensions, % with any problem
Anxiety/depression 96.6 24.7
Pain/discomfort 73.3 37.9
Usual activities 72.5 14.6
Mobility 33.8 17.1
Self-care 18.3 4.9
HADS UK adults (N¼ 1792)b
HADS-D 12.3 (4.5) 3.7 (3.1)
HADS-A 13.0 (4.0) 6.1 (3.8)
All data are presented as mean (SD) unless indicated otherwise. EQ-5D: Eu-
ropean Quality of Life-5 Dimensions questionnaire; SD: standard deviation;
VAS: Visual Analogue Scale; HADS-D: Hospital Anxiety and Depression
Scale-Depression subscale; HADS-A: Hospital Anxiety and Depression
Scale-Anxiety subscale.
a From Szende and Williams [41].
b From Crawford et al. [14].managed in primary care, with cross-sectional studies high-
lighting that fewer than half of these episodes are identified
during consultation largely because of somatic presentation
by patients [43]. Many primary care patients present with
a combination of physical, somatic and painful symptoms
rather than the classic emotional symptoms of depression
[18]. Further exploration of the FINDER data set willNot at all 818 (23.8)
A little bit 725 (21.1)
Moderately 872 (25.4)
Quite a bit 745 (21.7)
Extremely 275 (8.0)
Pain symptom location, SSI-28 pain-related items, patients bothered
moderately/quite a bit/a great deal
Headaches 1676 (49.0)
Soreness in muscles 1561 (46.0)
Pain in lower back 1557 (45.8)
Neck pain 1536 (44.9)
Pain in joints 1469 (43.1)
Pain/cramps in abdomen 1019 (30.1)
Pain in heart/chest 955 (26.3)
VAS scores
for pain,a mean (SD)
Overall pain 39.6 (28.8)
Severity of headaches 30.5 (29.5)
Severity of back pain 32.2 (30.7)
Severity of shoulder pain 24.7 (29.8)
Interference of overall pain with ability to
perform daily activities
39.2 (31.6)
Amount of time had pain while awake 42.0 (32.5)
Data presented as N (%) of patients unless indicated otherwise.
a During past week; VAS score 0e100.
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Fig. 3. SF-36 scores by pain group. Dotted line represents the general population norm (mean 50). Solid lines represent clinical depression norms (PCS mean 45.0;
MCS mean 34.8). A higher score indicates better quality of life. PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF,
social functioning; RE, role emotional; MH, mental health; MCS, mental component score; PCS, physical component score. Patients with no/mild pain had an over-
all VAS score <30 mm whereas patients with medically explained or unexplained pain had moderate/severe pain defined as an overall VAS pain score 30 mm.
63A. Garcia-Cebrian et al. / European Psychiatry 23 (2008) 57e65allow us to examine the influence of primary and second-
ary care settings in treatment outcomes.4.2. Criteria for patient inclusionAlmost half of the investigators in FINDER were PCPs and
therefore unlikely to administer psychiatric procedures to di-
agnose depression. Consistent with the observational nature
of the study, patient eligibility for study entry relied on a clin-
ical diagnosis of depression. In addition, patients completed
the HADS, which has excellent psychometric properties in
specialist and primary care populations [35,36]. According
to the subscale scores, 66% and 72% of patients had ‘probable
caseness’ of depression and anxiety, respectively, demonstrat-
ing that a clinical diagnosis of depression in a naturalistic
study may deviate from instrument-based diagnosis.4.3. Longitudinal designThe analysis described here is cross-sectional for patients
enrolled in the FINDER study and as such highlights the11.6 11.4 11.11.6
0
2
4
6
8
10
12
14
16
0 1 2 3
Number of SSI
M
e
a
n
 
H
A
D
S
-
D
 
s
c
o
r
e
I
n
c
r
e
a
s
i
n
g
 
s
e
v
e
r
i
t
y
Fig. 4. Depression score (mean HADS-D) according to number of pain-related item
sion subscale; SSI-28: somatic symptom inventory-28.important relationship between depression, quality of life
and pain. The longitudinal design of the study will enable
us to observe HRQoL improvements during treatment in
everyday clinical practice, as well as to increase the under-
standing of factors associated with those outcomes in further
analysis.4.4. FINDER baseline resultsHRQoL outcomes provide a broader view of the patient’s
overall well-being, compared with traditional depression rat-
ing scales. In some countries, like the UK, clinicians have
called to have HRQoL outcomes measured along with more
conventional outcome measures [1]. It is argued that patients
and clinicians differ in their assessment of the severity of ill-
ness and effects of treatment but the patient is the only valid
source of HRQoL information. HRQoL data in depression
are limited. Some consider HRQoL as a measure of impair-
ment, disability and handicap (in symptoms and function)
that can be labelled as ‘‘health status’’. Others argue that
this is too restrictive and a ‘‘needs based’’ approach should3 11.8 11.7
12.8
14.1
4 5 6 7
-28 pain-related items
s present on SSI-28. HADS-D: hospital anxiety and depression scale- depres-
64 A. Garcia-Cebrian et al. / European Psychiatry 23 (2008) 57e65be used [47]. In FINDER we refer HRQoL as a ‘‘health sta-
tus’’, measuring the level of impairment and physical and so-
cial disabilities in depressed patients.
HRQoL for patients entering FINDER was lower than pop-
ulation norms. In particular, the mean SF-36 MCS score was
more than two SDs below the population norm and about one
SD lower than the norm for clinical depression, whereas the
mean baseline PCS score was similar to norms. As expected
for depressed patients, FINDER participants were more im-
paired mentally than physically.
In patients with major depression studied in primary care,
those with higher depressive symptom scores had worse func-
tional status and HRQoL [17,27]. Factors such as clinical his-
tory, medical and psychiatric co-morbidity and characteristics
of the index depressive episode [39] have been reported to
affect the prognosis of depression. Though the majority of these
studies have been undertaken in specialist clinic samples, PCP
studies are also consistent with this observation [17]. The
FINDER population had considerable past psychiatric history,
with 45.1% of patients reporting at least one episode of depres-
sion in the previous 2 years. The inclusion of recurrent and first
episode patients will enable us to investigate further whether
differences exist in their HRQoL outcomes.
Other factors relevant to HRQoL in depression, including
anxiety, somatic and painful physical symptoms, have re-
ceived less investigation. Indeed, many studies evaluating
the association between depression and pain have assessed
the emotional and psychological impacts of underlying medi-
cal disorders (i.e. secondary depression). However, pain is
a common symptom associated with depression, and the pres-
ence of pain can complicate its diagnosis and treatment [5,32].
In FINDER, 56.3% of depressed patients had moderate/severe
pain, whether medically explained or unexplained at baseline.
Nevertheless, the interesting question is to what extent
painful symptoms affect HRQoL outcomes in depression? In
this cross-sectional analysis of FINDER baseline data, we
found that pain interfered with normal work in over half of
the patients. Moreover, increasing pain severity and a higher
number of pain-related symptoms were associated with more
severe depression, although causation cannot be inferred
from these data. Data from previous studies indicate that
more severe pain predicts poorer depression and HRQoL out-
comes [4], and further research is needed to explore the links
between depression, HRQoL and pain.4.5. Study limitationsSeveral limitations should be considered when interpreting
the results of FINDER: (1) the sample was limited to patients
initiating antidepressant treatment, thus excluding those with
unrecognised depression, those untreated and those exclu-
sively receiving a non-pharmacological treatment; (2) data
collected retrospectively for the previous 2 years before study
entry may be affected by recall bias; (3) the pre-specified lists
of psychiatric, physical and functional conditions may not be
comprehensive enough to capture all co-morbid conditions
present; (4) the pre-specified list may have also promptedphysicians to record certain disorders that may not withstand
further diagnostic confirmation; (5) HRQoL instruments
used in the study (e.g. SF-36 and EQ-5D) partly measure
concepts that are also contained in depression instruments.
In addition, it is also worth noting that HADS was initially
designed as a screening tool for depression. However, it has
been used for the evaluation of depression, and a review of
data has shown that it is sensitive to changes during the course
of disease and in response to psychotherapeutic and psycho-
pharmacological interventions [26]. Lastly, observational
studies are in general accompanied by a number of potential
weaknesses, such as selection bias, observer bias and con-
founding, mainly resulting from the absence of randomisation
[23,24], e.g. it is possible that physicians participating in the
study had a particular interest in psychiatry and were therefore
not representative of the general PCP population. As the
extent of the bias due to non-observed covariates is usually
unknown, statistical techniques are limited in their ability to
fully correct for those. However, the merits of an observa-
tional study lay in being complementary evidence to those
derived from RCTs [12].
In conclusion, with over 3500 patients, this is the largest pro-
spective observational study of depression and HRQoL to date.
HRQoL of patients at enrolment demonstrates a substantial
impairment and indicates an association between depression,
HRQoL and pain. Further analysis of data from the FINDER
study will provide important advances in our understanding
of the factors influencing HRQoL outcomes in depression in
everyday clinical practice.
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